Previous close | 3.9400 |
Open | 3.9000 |
Bid | 3.6400 x 3000 |
Ask | 3.6400 x 1000 |
Day's range | 3.5500 - 3.9400 |
52-week range | 0.3710 - 5.5800 |
Volume | |
Avg. volume | 279,268 |
Market cap | 104.254M |
Beta (5Y monthly) | 1.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2800 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.50 |
BOSTON, May 06, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services ("CMS"), through their regional contractors known as the DME MACs, have remitted and paid lump sum reimbursements to the Company and are beginning to reimburse orthotics and prosthetics ("O&P") providers f
BOSTON, May 01, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024.
BOSTON, March 28, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors.